Susquehanna International Group, LLP Aravive, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	SELL	$1.25 - $1.92 $55,250 - $84,864	-44,200 Reduced 42.91%	58,800 $74,000
Q1 2023 May 16, 2023	SELL	$1.29 - $2.46 $53,148 - $101,352	-41,200 Reduced 28.57%	103,000 $206,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $1.83 $173,040 - $263,886	144,200 New	144,200 $190,000
Q3 2021 Nov 15, 2021	BUY	$3.67 - $5.8 $21,286 - $33,640	5,800 Added 26.36%	27,800 $103,000
Q2 2020 Aug 14, 2020	SELL	$5.18 - $14.81 $344,470 - $984,865	-66,500 Reduced 75.14%	22,000 $256,000
Q4 2019 Feb 14, 2020	BUY	$6.21 - $14.02 $410,481 - $926,722	66,100 Added 295.09%	88,500 $1.21 Million
Q3 2019 Nov 14, 2019	BUY	$5.2 - $8.68 $5,720 - $9,548	1,100 Added 5.16%	22,400 $168,000
Q2 2019 Aug 14, 2019	BUY	$5.65 - $7.5 $1,130 - $1,500	200 Added 0.95%	21,300 $128,000
Q1 2019 May 15, 2019	SELL	$3.35 - $8.27 $30,820 - $76,084	-9,200 Reduced 30.36%	21,100 $149,000
Q4 2018 Feb 14, 2019	BUY	$3.23 - $8.7 $97,869 - $263,610	30,300 New	30,300 $107,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.